Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹5,654 Cr
Revenue (TTM)
₹1,690 Cr
Net Profit (TTM)
₹-139 Cr
ROE
-13.6 %
ROCE
-1.9 %
P/E Ratio
--
P/B Ratio
6.3
Industry P/E
37.82
EV/EBITDA
27.6
Div. Yield
0 %
Debt to Equity
0.3
Book Value
₹48
EPS
₹-0.8
Face value
1
Shares outstanding
187,921,012
CFO
₹623.46 Cr
EBITDA
₹1,037.70 Cr
Net Profit
₹155.95 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Camlin Fine Sci
| 135.6 | 51.1 | 69.2 | 190.4 | 43.9 | 45.5 | 11.1 |
|
BSE Commodities
| 5.6 | -1.0 | 5.2 | -0.3 | 18.6 | 25.8 | -- |
|
BSE Small Cap
| -4.4 | 1.8 | 13.8 | 1.9 | 29.5 | 33.7 | 17.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Camlin Fine Sci
| -2.4 | -15.2 | 23.1 | 4.5 | 42.0 | 55.8 | -59.1 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Commodities
| 8.1 | 17.5 | 1.2 | 61.5 | 26.1 | -4.6 | -19.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Camlin Fine Sci
|
301.6 | 5,653.6 | 1,689.8 | -158.6 | 5.7 | -1.3 | -- | 6.3 |
| 775.7 | 10,288.3 | 838.7 | 158.4 | 23.4 | 7.7 | 64.9 | 4.6 | |
| 633.1 | 7,806.2 | 1,041.0 | 162.1 | 22.6 | 9.1 | 48.1 | 4.2 | |
| 413.8 | 6,520.4 | 4,346.1 | -110.4 | 0.5 | -5.8 | -- | 3.2 | |
| 11,366.5 | 9,011.0 | 778.1 | 135.5 | 16.8 | 16.2 | 66.5 | 10.0 | |
| 846.2 | 5,487.4 | 110.7 | 1.6 | 1.4 | 0.6 | -- | 17.7 | |
| 4,028.5 | 9,359.4 | 2,109.4 | 331.2 | 19.0 | 14.4 | 28.3 | 3.9 | |
| 700.7 | 11,163.2 | 4,177.6 | 251.2 | 8.7 | 8.7 | 44.4 | 3.8 | |
| 192.9 | 5,340.5 | 2,985.4 | 113.5 | 5.2 | 6 | 47.1 | 2.8 | |
| 2,342.9 | 9,137.0 | 2,101.2 | 184.8 | 15.1 | 17.8 | 48.9 | 8.3 |
2 min read•By Yash Rohra
Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers... shelf-life solutions, which include antioxidants comprises Butylated Hydroxy Toluene and Ascorbyl palmitate; and emulsifiers, mold inhibitors, antibacterial agents, toxin binders, pellet binders, disinfectants, energizers, preservatives, thickening agents, and growth promoters, as well as plant-based antioxidants, such as mixed tocopherols, green tea extract, and rosemary extract that are used to enhance the shelf life under the Xtendra and NaSure brands. It also provides aroma ingredients, including vanillin and ethyl vanillin; health and wellness products; and performance chemicals, such as hydroquinone and catechol. Its products are used in food and beverage, pet food, animal nutrition, rendering, health and wellbeing, chemicals, biofuel, aroma technical, fragrance, and flavor industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India. Read more
Incorporated
1993
Chairman
Ashish Dandekar
Managing Director
Nirmal V Momaya
Group
S Dandekar
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Camlin Fine Sciences Ltd stood at ₹ 2,024 Cr as on 31-Mar-25
The share price of Camlin Fine Sciences Ltd is ₹301.59 (NSE) and ₹300.85 (BSE) as of 20-Jun-2025 IST. Camlin Fine Sciences Ltd has given a return of 43.92% in the last 3 years.
Camlin Fine Sciences Ltd has a market capitalisation of ₹ 5,654 Cr as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Camlin Fine Sciences Ltd is 6.27 times as on 20-Jun-2025, a 100% premium to its peers’ median range of 3.14 times.
Since, TTM earnings of Camlin Fine Sciences Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Camlin Fine Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Camlin Fine Sciences Ltd.
Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include antioxidants comprises Butylated Hydroxy Toluene and Ascorbyl palmitate; and emulsifiers, mold inhibitors, antibacterial agents, toxin binders, pellet binders, disinfectants, energizers, preservatives, thickening agents, and growth promoters, as well as plant-based antioxidants, such as mixed tocopherols, green tea extract, and rosemary extract that are used to enhance the shelf life under the Xtendra and NaSure brands. It also provides aroma ingredients, including vanillin and ethyl vanillin; health and wellness products; and performance chemicals, such as hydroquinone and catechol. Its products are used in food and beverage, pet food, animal nutrition, rendering, health and wellbeing, chemicals, biofuel, aroma technical, fragrance, and flavor industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.
The prominent promoters of Camlin Fine Sciences Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Ashish Subhash Dandekar |
10.52%
|
|
Infinity Direct Holdings |
10.41%
|
|
Anfima Nv |
9.03%
|
|
Infinity Holdings |
6.34%
|
|
Infinity Direct Holdings Sidecar I |
4.93%
|
The chairman of the company is Ashish Dandekar, and the managing director is Nirmal V Momaya.
The promoters of Camlin Fine Sciences Ltd have pledged 5.32% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
11,163
|
|
|
10,288
|
|
|
9,359
|
|
|
9,137
|
|
|
9,011
|
|
|
7,806
|
|
|
6,520
|
|
|
5,487
|
|
|
5,340
|
| Camlin Fine Sciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-1.33
|
|
Operating margin(%)
|
5.68
|
|
Net Margin(%)
|
-7.93
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Camlin Fine Sciences Ltd was ₹-139 Cr.
₹4.90
(
